Success Story: EB-1A Approval for an Infectious Diseases Specialist Recognized Through Publication, Citation Reliance, and Peer-Review Trust
Client’s Testimonial:
"The process was professional and thorough. While I do have a significant citation list and larger involvement across multiple systems, being able to frame it in a way that passed the EB-1A merits without any challenge. I thank Chen for a personalized platform to achieve this goal."
On February 19th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Physician/Associate Professor in the Field of Infectious Diseases (Approval Notice).
General Field: Infectious Diseases
Position at the Time of Case Filing: Physician/Associate Professor
Country of Origin: Canada
Country of Residence at the Time of Filing: Canada
Approval Notice Date: February 19th, 2026
Processing Time: 1 month, 10 days (Premium Processing Upgrade Requested)
Case Summary:
Some infectious disease breakthroughs begin as a clinical safety question and end as guidance that reshapes how health systems protect patients and healthcare workers. This EB-1A approval highlights an infectious diseases specialist whose work strengthens evidence-based treatment and infection control, including widely relied upon research evaluating COVID-19 vaccine safety in individuals with excipient allergies. At the time of filing, the client planned to continue this work in the United States in a physician-research role focused on infection prevention measures, therapies, and vaccination programs within hospital systems.
Extraordinary Research Contributions In the petition, North America Immigration Law Group (Chen Immigration Law Associates) presented the client’s record as centered on original contributions of major significance that help clinicians and public health leaders make defensible decisions under uncertainty. In privacy-protective terms, this included rigorous evaluation of vaccine safety for allergy-risk populations, research clarifying the protective effectiveness of respiratory protection strategies for healthcare workers, and evidence-driven analysis relevant to transmission dynamics and inequities in infectious disease outcomes. The filing framed these contributions as practical tools that other experts can apply to strengthen patient safety, occupational protection, and outbreak response.
Academic Contributions and Recognition To demonstrate sustained influence, the petition documented a substantial body of scholarly authorship: 47 peer-reviewed journal articles (13 first-authored) and 5 abstracts (2 first-authored). This work received 1,369 citations, reflecting strong independent reliance by researchers who used the client’s findings as building blocks for further investigations. The petition also documented at least 20 completed peer reviews, reflecting repeated trust in the client’s judgment to evaluate other experts’ work in selective clinical and infectious disease publication venues.
These metrics were not treated as self-explanatory. We tied them to how the field signals extraordinary ability in practice: repeated acceptance in rigorous venues reflects consistent success under expert scrutiny, citations show that other specialists rely on the work to support their own conclusions, and peer-review invitations demonstrate professional trust beyond the client’s own claims.
Expert Endorsements The petition included five expert recommendation letters, including independent perspectives, describing why the client’s work is influential in infectious disease treatment and control and why it matters beyond any single project.
One expert stated: “These achievements position him as a key contributor to interdisciplinary infectious disease research who must be retained within the U.S. to maintain national leadership in public health preparedness and vaccine confidence initiatives.”
EB1A Approval and Outlook The I-140 EB-1A petition was approved, recognizing a cohesive record of original contributions of major significance, influential scholarly authorship with strong independent citation uptake, and sustained peer-review trust supporting a final merits showing of extraordinary ability. With this approval, the client is well-positioned to continue advancing evidence-based infectious disease strategies that strengthen patient safety and healthcare system preparedness in the United States.